Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026

Adicet Bio, Inc.

2026-Q1 EPS reported -$1.88

Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.
Cash, cash equivalents and ST investments $137.6M at March 31, 2026; expected runway into H2 2027.
Phase 1 prula-cel update in mid-2026 with at least 20 LN/SLE patients, min 6 months follow-up.
FDA interaction in Q2 2026 to inform potential pivotal trial design; plan to start pivotal program in H2 2026.
Regulatory filing for ADI-212 in mCRPC planned for Q3 2026; Phase 1 enrollment expected Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Adicet Bio, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $20.2 million, or a net loss of $1.88 per basic and diluted share, EPS a net loss of $1.88 per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was $20.2 million, or a net loss of $1.88 per basic and diluted share
EPS: a net loss of $1.88 per basic and diluted share
Result: reported results

Exact text from the filing

On May 13, 2026, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001720580-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.